logo
Lotus Emeya S review: Breakthrough British electric sports sedan is a performance powerhouse, Lifestyle News

Lotus Emeya S review: Breakthrough British electric sports sedan is a performance powerhouse, Lifestyle News

AsiaOne27-04-2025

The name Lotus in the automotive world conjures up images of a two-door sports car that's lightweight and uncompromising. A Lotus sports car is designed for the hardcore enthusiast, who values driving enjoyment and purity above all else.
But unless you're able to charge an arm and a leg for them like Ferrari or Lamborghini, selling sports cars alone isn't exactly a profitable enterprise. And in this modern era of electrification, Lotus has had to evolve and adapt in order to survive.
Enter the Emeya, Lotus' first ever electric four-door sports sedan. Why has Lotus made an electric sedan?
First of all, we need to look at the direction Lotus has taken in recent years.
As mentioned earlier, Lotus has spent most of its history making pure sports cars, a venture that earned it respect and some success, but not financial riches.
For much of the 21st century, Lotus was owned by Malaysian carmaker Proton, following a spell of instability during the 1980s and 90s when it was being passed around various different owners.
But in 2017, Chinese carmaker conglomerate Geely bought a major controlling stake of Lotus from Proton, and kickstarted the brand revolution that is starting to bear fruit today.
Geely recognised that electrification was a necessary step in today's automotive world, and it had plans to transition Lotus to an all-electric brand by 2028.
In 2021, it put out Lotus' first electric model, the Evija. It was a sports car with a limited production run, and had four electric motors that produced a total power output of over 2,000hp.
The Evija was meant to showcase how Lotus' famed automotive engineering prowess can be applied to the electric car era, and it gave the brand enough confidence to pivot towards bolder steps.
The next breakthrough was in 2023, when Lotus unveiled the Electre, its first ever SUV that was also electric-powered. It sent shockwaves throughout the industry, as few could ever imagine Lotus releasing an SUV.
It seemingly went against everything the brand stood for, but the car went on to receive rave reviews, and demonstrated that Lotus could apply its technical capabilities onto a new form without sacrificing too much of the driving enjoyment that its customers expect from its cars.
The Emeya then is a natural progression on that trajectory. A sports sedan like the Emeya is still a product that's somewhat un-Lotus-like, but it's certainly less controversial than an SUV, so it's probably somewhat more palatable to enthusiasts.
More importantly, cars like the Electre and Emeya open up the Lotus brand to a wider audience, potentially giving it the financial stability to become a more sustainable business. What's the Emeya like?
The car we're driving is the Emeya S, which is the mid-spec model that costs $448,800 without COE.
It sits between the base Emeya ($427,800 without COE) and the high-performance Emeya R ($563,800 without COE). The difference between the base model and the S is mostly down to equipment, with the S featuring high performance brakes, and additional features like a carbon fibre spoiler and glass roof.
The Emeya R is the hardcore version with a lot more power, but in Singapore's context the R would be a bit of an overkill, unless you intend to take your Emeya to the track regularly.
The first thing you'll note about the car is that it is very long. It stretches to over 5 metres in length and 2 metres in width, so you do have to be extra careful in manoeuvring this beast around tighter carparks.
The car's design manages to be sleek and aggressive without shouting too loud. The front end, with its slim headlights and sharp nose, boasts a scowl that lets people know that it means business, while the full-width taillight bar at the rear accentuates the Emeya's sizeable proportions.
It is the inside though that makes the Emeya a Lotus like no other. Previous Lotus sports cars have generally boasted of spartan and barebones interiors, but the Emeya's is a world of luxury in comparison.
The biggest thing, literally, is the space you get. With its generous wheelbase that's over 3 metres long, there's plenty of room for occupants, especially those in the rear, to stretch their legs and perhaps play a game of kickball between themselves.
Up front, you get a sleek-looking dashboard made from high-quality materials that truly befits the Emeya's status as a premium contender. It's a fairly minimalist design, but there are nice touches like the small screen in front of the front passenger to control some of the infotainment options.
Like many newer EVs these days, most of the controls are accessed via the central touchscreen. In the Emeya, you get a rather large 15.6-inch screen that is powered by a pretty fast processor, resulting in quick response times and sharp graphics.
Another interesting highlight is the pretty clever electro-chromic glass roof where you can choose to light or shade selected segments to allow just the right amount of light in as you wish, or create a fancy pattern to wow your passengers. It's a $17,000 option though, so it's quite a price to pay for what is really a fun feature. Does it drive like a Lotus?
If you're expecting the same kind of pure driving experience as Lotus' iconic sports cars, then unfortunately you're not quite going to get that in the Emeya.
It's worth bearing in mind that, at the end of the day, the Emeya is still a large EV with a heavy battery, and its weight of over 2.5 tonnes is hard to ignore.
That said, it still manages to hide it pretty well, partly by simply overpowering it with brute force. The Emeya S puts out a total of 603hp and 710Nm of torque from its dual electric motors, allowing it to go from 0-100km/h in just 4.2 seconds.
It certainly does feel as quick as the numbers suggest, with the car picking up speed with the sort of urgency that not entirely unexpected from a performance-focused EV actually.
And yet it doesn't feel as abrupt or jolting as some other high-powered EVs under hard acceleration. Instead, the Emeya delivers its power smoothly and effectively such that it doesn't feel overwhelming.
It certainly makes for a great long distance cruiser, and that is supplemented by its excellent ride quality, which is not something one can say about Lotus sports cars from the past. The suspension is firm but not unduly uncomfortable, and one could drive the Emeya all day without emerging with a backache at the end of the journey.
And despite its size and weight, the Emeya acquits itself relatively well in the corners, for a car of its type anyway. It's not going to have same sort of laser precision handling as the Lotus sports cars of yore, but it has a steering that offers plenty of feel, and a chassis that feels taut and capable of letting the car hang on gamely when pushed hard.
It's probably helped by the optional Dynamic Handling Pack (which costs an eye-popping $42,000) fitted on the test car that includes rear wheel steering and active anti-roll bars, and they combine to give the Emeya a sense of nimbleness that seemingly defies its dimensions.
With all that performance capability, it's easy to forget the Emeya's electric prowess. The large 102kWh battery offers a claimed range of 540km, but you'll probably get closer to the high 400s in the real world.
Charging time is rated at 14 minutes from 10 to 80 per cent using a 400kW rapid charger, but our fastest public charger is only about half that rate, so you can expect a charge time of around 20 minutes or so. What is the point of the Emeya then?
It's fair to say that if you're looking for a high-performance electric sedan, there are no shortage of options available out there for your consideration.
In terms of capability, the closest competitor to the Emeya would be the Porsche Taycan. However, to achieve the same sort of performance ability as the Emeya S, you'll have to go for the top-spec Taycan Turbo, which costs almost double the price of the Lotus.
Viewed in that perspective, the Emeya doesn't seem too bad in comparison relatively speaking. It may not be quite like the Lotus you remember, but it certainly will be a Lotus you won't forget.
[[nid:696570]]
ben.chia@asiaone.com
No part of this article can be reproduced without permission from AsiaOne.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Taiwan imposes technology export controls on Huawei, SMIC
Taiwan imposes technology export controls on Huawei, SMIC

Business Times

time2 hours ago

  • Business Times

Taiwan imposes technology export controls on Huawei, SMIC

Taiwan has blacklisted Huawei Technologies and Semiconductor Manufacturing International Corp (SMIC), dealing another major blow to the two companies spearheading China's efforts to develop cutting-edge AI chip technologies. Taiwan's International Trade Administration has included Huawei, SMIC and several of their subsidiaries in an update of its so-called strategic high-tech commodities entity list, according to the latest version that was made available on its website on Saturday (Jun 14). It didn't publicly announce the change. According to Taiwan's existing regulations, local companies will require approval from the island's government before they can ship anything to users on the entity list. In 2023, Bloomberg News reported that several Taiwanese companies were helping Huawei build infrastructure for an under-the-radar network of chip plants across southern China. The new restrictions imposed by Taipei are likely to at least partially cut off Huawei and SMIC's access to Taiwan's plant construction technologies, materials and equipment essential to build AI semiconductors, such as those made by Taiwan Semiconductor Manufacturing Co (TSMC) for the likes of Nvidia Corp. In Huawei's case, several of its overseas units including in Japan, Russia and Germany were also captured in the update to Taiwan's entity list. Both Huawei and SMIC – and some of their subsidiaries – are also on the US entity list, which has significantly limited the companies' ability to acquire foreign technology. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up Huawei and SMIC didn't immediately respond to requests for comment outside of regular office hours. While Taiwan has for years imposed certain blanket bans on the shipments of critical chipmaking equipment including lithography machines to China, it hasn't included leading Chinese tech companies or chipmakers on its entity list previously. TSMC, the go-to chipmaker for Apple and Nvidia, cut off its supplies to Huawei in 2020 because of US export controls. Huawei, together with SMIC, shocked American politicians in 2023 by releasing an advanced, made-in-China 7-nanometre chip. While the two are struggling to improve their technologies due to various curbs, they are still China's best hope to help fill in the AI chip gap left by a lack of Nvidia's most sophisticated semiconductors. Tensions between Taiwan and China also stepped up a notch earlier this year after Taiwan President Lai Ching-te labelled China a 'foreign hostile force' for the first time and unveiled wide-ranging measures to counter infiltration efforts. China claims the self-governing democracy as its territory and has vowed to unify with Taiwan, using force if necessary. BLOOMBERG

China's biotech moment ignites a 60% stock rally that beats AI
China's biotech moment ignites a 60% stock rally that beats AI

Business Times

time2 hours ago

  • Business Times

China's biotech moment ignites a 60% stock rally that beats AI

China's biotechnology stocks have shaken off a four-year slump to be among the hottest performers in Asia this year and funds are tipping further gains. The Hang Seng Biotech Index has surged more than 60 per cent since the start of January amid investor enthusiasm over a pair of billion-dollar deals involving foreign firms licensing Chinese drugs. Share gains at two highly anticipated listings of local producers have further burnished the sector's appeal. 'China biotech is no longer just an emerging story – unlike 10 years ago – it is now a disruptive force reshaping global drug innovation,' said Yiqi Liu, senior investment analyst at Exome Asset Management in New York. 'The science is real, the economics are compelling, and the pipeline is starting to deliver.' The surge in China-listed biotech firms is further evidence that the mainland is becoming a centre for global innovation. The rally in the sector this year outpaces the 17 per cent gain in China's tech stocks that was driven by the release of DeepSeek's breakthrough artificial-intelligence app in January. A major reason for the share gains were two mega-sized licensing deals. Pfizer said on May 19 that it had agreed to pay a record US$1.25 billion to license an experimental cancer drug from China's 3SBio, and also invest US$100 million in the firm's shares. Two weeks later, Bristol-Myers Squibb said it would pay Germany's BioNTech as much as US$11.5 billion to license a cancer drug that BioNTech had itself licensed from China's Biotheus in 2023. Some of the gains in biotech shares this year have been stratospheric. 3SBio has surged 283 per cent, topping a Bloomberg gauge of global biotech stocks. RemeGen, which develops antibody drugs, has climbed more than 270 per cent after saying it was approached by multinational pharmaceutical firms for potential licensing deals. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up China's growing influence through pharmaceutical mergers and acquisitions and deal-making is also causing investors to take note. In the first quarter alone, the value of such deals involving local players doubled from the year before to US$36.9 billion. That amount made up more than half the global total of US$67.5 billion. Chinese biotech companies are having 'their own DeepSeek moment', said Dong Chen, chief Asia strategist at Pictet Wealth Management in Hong Kong. There is more upside from here, he said. Investor interest in biotech – which involves the use of living organisms to make medicines and other products – can be seen in the big runup at recent initial public offerings. Shares of Duality Biotherapeutics, which develops cancer treatments, more than doubled on their first day of trading in Hong Kong on Apr 15. Jiangsu Hengrui Pharmaceuticals, the nation's largest drugmaker by market value, saw its stock jump 25 per cent on its May 23 debut, even after being issued at the top end of the marketed range. Duality has now risen 189 per cent since its IPO, while Jiangsu has gained 31 per cent. Still, some say the rally may be getting stretched. 'Bears, mostly healthcare specialists, plan to take profit at this point, and some investors prefer the healthcare laggers with capability of constant dividend payout and stable revenue growth,' Bank of America analysts including Ethan Cui in Hong Kong wrote in a research note this month. Some investors also said they viewed the rush of recent licensing deals as a one-off, and they were refusing to grant valuation multiples to the companies, the analysts wrote. Talent returns While the recent ratcheting up of trade tensions between the US and China has been a negative for many mainland firms, it's also resulted in talent flowing back to China and creating more research-and-development capability, according to Nicholas Chui, a Chinese equity fund manager at Franklin Templeton in Hong Kong. Jefferies is also bullish, saying the increase in US tariffs is unlikely to prove an obstacle to Chinese biotech firms. Many of the Chinese biotech companies already have US partners and are therefore considered as service providers rather than product exporters, said Cui Cui, head of Asia healthcare research at the company in New York. BLOOMBERG

Taiwan adds China's Huawei, SMIC to export control list
Taiwan adds China's Huawei, SMIC to export control list

Straits Times

time4 hours ago

  • Straits Times

Taiwan adds China's Huawei, SMIC to export control list

Semiconductor Manufacturing International Corporation has been added to Taiwan's export control list along with Huawei Technologies. PHOTO: REUTERS TAIPEI - Taiwan's government has added China's Huawei Technologies and Semiconductor Manufacturing International Corp (SMIC) to its export control list, which includes other proscribed organisations like the Taliban and al Qaeda. Inclusion on the economy ministry's trade administration's strategic high-tech commodities entity list means Taiwanese companies will need government approval before exporting any products to the companies. The companies were included in an updated version of the ministry's trade administration's website late on June 14 . Neither company nor the economy ministry immediately responded to requests for comment outside of office hours at the weekend. Taiwan is home to TSMC, the world's largest contract chipmaker and a major supplier of chips to AI darling Nvidia. Both Huawei and SMIC have been working hard to catch up in the chip technology race. Taiwan, which China claims as its own territory despite the strong objections of Taipei's government, already has tight chip export controls when it comes to Taiwanese companies either manufacturing in the country or supplying Chinese firms. Huawei, which is at the centre of China's AI ambitions, is on a US Commerce Department trade list that essentially bars it from receiving US goods and technology, as well as foreign-made goods such as chips from companies like TSMC made with US technology. In October 2024, TechInsights, a Canadian tech research firm, took apart Huawei's 910B AI processor and found a TSMC chip in it. The multi-chip 910B is viewed as the most advanced AI accelerator mass-produced by a Chinese company. TSMC suspended shipments to China-based chip designer Sophgo, whose chip matched the one in the Huawei 910B and, in November 2024, the US Commerce Department ordered TSMC to halt shipments of more chips to Chinese customers. Taiwan's government has also repeatedly vowed to crack down on what it says are efforts by Chinese companies, including SMIC, to steal technology and entice chip talent away from the island. SMIC is China's largest chipmaker and has ramped up investment to expand production capacity and strengthen China's domestic semiconductor capability in the face of sweeping US export controls. REUTERS Join ST's Telegram channel and get the latest breaking news delivered to you.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store